Anticipated Shortage

CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE

OMEGA LABORATORIES LIMITED

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE in Canada?

A shortage of CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE 2MG is expected: the manufacturer reported it to Health Canada as an anticipated shortage (last updated November 11, 2026), but it has not started yet.

Why is CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE not available?

The reason the manufacturer reported: Disruption of the manufacture of the drug.

When will CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE be available again?

The manufacturer's estimated resolution date is January 15, 2027. This is an estimate and can change; follow this page to get an email when the status changes.

Can I still get this?Possibly — same-ingredient product records found

StatusAnticipated Shortage

Same-ingredient products on file1 product

Expected resolution~2 months remaining (estimate)

Affected strength2MG

Report last updated2026-11-11

Checked by MedShort2026-11-12

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Closest Matches

CISATRACURIUM BESYLATE INJECTION USP MULTI-DOSE

STERIMAX INC

2MG · DIN 02563266

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

What this means

Does this mean my pharmacy is already out of stock?

No — this shortage hasn't started yet. It's an early warning that supply may become tight, based on information from the manufacturer.

What should I do?

This product is usually given in a hospital or clinic, where the pharmacy team manages supply. If you're scheduled to receive it, ask your care team.

Estimated Resolution

2027-01-15

~2 months remaining (estimate)

This is the manufacturer's estimated date, not a guarantee — actual resolution may come earlier or later.

Have you checked a pharmacy recently?

No community reports yet — be the first to share what you found.

Community reports are not verified by a pharmacy and may reflect a small sample size. This is not a guarantee of current stock.

DIN

02408813

Strength

2MG

Dosage Form

SOLUTION

Route

INTRAVENOUS

Active Ingredient

CISATRACURIUM

Tier

Unrated

Last Updated

2026-11-11

Reason for Shortage

Disruption of the manufacture of the drug.

Source

View original report on healthproductshortages.ca ↗

Past Reports for This Drug

CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE has 2 shortage/discontinuation reports on file — this is one of them.

2024-06-25

Shortage Avoided

Demand increase for the drug.

Other Products from OMEGA LABORATORIES LIMITED

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

0.9% SODIUM CHLORIDE INJECTION USP

9MG · DIN 02150204

AMIKACIN SULFATE INJECTION

250MG · DIN 02486717

AMINOPHYLLINE INJ 25MG/ML

25MG · DIN 00582662

AMINOPHYLLINE INJ 50MG/ML

50MG · DIN 00582654

BAXEDIN 2% - 70%

DIN 02251477

BAXEDIN LIQ 20%

20% · DIN 00658413